Literature DB >> 29162563

FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor.

Leili Ran1, Yuedan Chen1,2, Jessica Sher1, Elissa W P Wong1, Devan Murphy1, Jenny Q Zhang1, Dan Li1, Kemal Deniz3, Inna Sirota4, Zhen Cao1,2, Shangqian Wang1, Youxin Guan1, Shipra Shukla1, Katie Yang Li5, Alan Chramiec5,6, Yuanyuan Xie1, Deyou Zheng7,8,9, Richard P Koche5, Cristina R Antonescu10, Yu Chen11,2,12,13, Ping Chi11,2,12,13.   

Abstract

The cellular context that integrates upstream signaling and downstream nuclear response dictates the oncogenic behavior and shapes treatment responses in distinct cancer types. Here, we uncover that in gastrointestinal stromal tumor (GIST), the forkhead family member FOXF1 directly controls the transcription of two master regulators, KIT and ETV1, both required for GIST precursor-interstitial cells of Cajal lineage specification and GIST tumorigenesis. Further, FOXF1 colocalizes with ETV1 at enhancers and functions as a pioneer factor that regulates the ETV1-dependent GIST lineage-specific transcriptome through modulation of the local chromatin context, including chromatin accessibility, enhancer maintenance, and ETV1 binding. Functionally, FOXF1 is required for human GIST cell growth in vitro and murine GIST tumor growth and maintenance in vivo The simultaneous control of the upstream signaling and nuclear response sets up a unique regulatory paradigm and highlights the critical role of FOXF1 in enforcing the GIST cellular context for highly lineage-restricted clinical behavior and treatment response.Significance: We uncover that FOXF1 defines the core-regulatory circuitry in GIST through both direct transcriptional regulation and pioneer factor function. The unique and simultaneous control of signaling and transcriptional circuitry by FOXF1 sets up an enforced transcriptional addiction to FOXF1 in GIST, which can be exploited diagnostically and therapeutically. Cancer Discov; 8(2); 234-51. ©2017 AACR.See related commentary by Lee and Duensing, p. 146This article is highlighted in the In This Issue feature, p. 127. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29162563      PMCID: PMC5809271          DOI: 10.1158/2159-8290.CD-17-0468

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  67 in total

1.  Protein degradation: Prime time for PROTACs.

Authors:  Raymond J Deshaies
Journal:  Nat Chem Biol       Date:  2015-09       Impact factor: 15.040

2.  FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Authors:  Mathieu Lupien; Jérôme Eeckhoute; Clifford A Meyer; Qianben Wang; Yong Zhang; Wei Li; Jason S Carroll; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2008-03-21       Impact factor: 41.582

3.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome.

Authors:  Nathaniel D Heintzman; Rhona K Stuart; Gary Hon; Yutao Fu; Christina W Ching; R David Hawkins; Leah O Barrera; Sara Van Calcar; Chunxu Qu; Keith A Ching; Wei Wang; Zhiping Weng; Roland D Green; Gregory E Crawford; Bing Ren
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

4.  Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.

Authors:  Georg Petzold; Eric S Fischer; Nicolas H Thomä
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

5.  Two deletions overlapping a distant FOXF1 enhancer unravel the role of lncRNA LINC01081 in etiology of alveolar capillary dysplasia with misalignment of pulmonary veins.

Authors:  Przemyslaw Szafranski; Avinash V Dharmadhikari; Jennifer A Wambach; Chris T Towe; Frances V White; R Mark Grady; Pirooz Eghtesady; F Sessions Cole; Gail Deutsch; Partha Sen; Paweł Stankiewicz
Journal:  Am J Med Genet A       Date:  2014-05-19       Impact factor: 2.802

6.  Involvement of hepatocyte nuclear factor 3 in endoderm differentiation of embryonic stem cells.

Authors:  M Levinson-Dushnik; N Benvenisty
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

7.  Clinical management of gastrointestinal stromal tumors: before and after STI-571.

Authors:  Ronald P Dematteo; Michael C Heinrich; Wa'el M El-Rifai; George Demetri
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

8.  Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.

Authors:  Daniel Morgensztern; Saiama Waqar; Janakiraman Subramanian; Kathryn Trinkaus; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

9.  The forkhead transcription factor Foxf1 is required for differentiation of extra-embryonic and lateral plate mesoderm.

Authors:  M Mahlapuu; M Ormestad; S Enerbäck; P Carlsson
Journal:  Development       Date:  2001-01       Impact factor: 6.868

10.  Integrated genome browser: visual analytics platform for genomics.

Authors:  Nowlan H Freese; David C Norris; Ann E Loraine
Journal:  Bioinformatics       Date:  2016-03-16       Impact factor: 6.937

View more
  25 in total

1.  Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.

Authors:  Annmarie Ramkissoon; Katherine E Chaney; David Milewski; Kyle B Williams; Rory L Williams; Kwangmin Choi; Adam Miller; Tanya V Kalin; Joseph G Pressey; Sara Szabo; Mohammad Azam; David A Largaespada; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2019-04-01       Impact factor: 12.531

2.  Gastroparesis is associated with decreased FOXF1 and FOXF2 in humans, and loss of FOXF1 and FOXF2 results in gastroparesis in mice.

Authors:  Brian Paul Herring; April M Hoggatt; Anita Gupta; John M Wo
Journal:  Neurogastroenterol Motil       Date:  2018-12-19       Impact factor: 3.598

3.  COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors.

Authors:  Yuanyuan Xie; Zhen Cao; Elissa Wp Wong; Youxin Guan; Wenfu Ma; Jenny Q Zhang; Edward G Walczak; Devan Murphy; Leili Ran; Inna Sirota; Shangqian Wang; Shipra Shukla; Dong Gao; Simon Rv Knott; Kenneth Chang; Justin Leu; John Wongvipat; Cristina R Antonescu; Gregory Hannon; Ping Chi; Yu Chen
Journal:  J Clin Invest       Date:  2018-03-05       Impact factor: 14.808

4.  The S52F FOXF1 Mutation Inhibits STAT3 Signaling and Causes Alveolar Capillary Dysplasia.

Authors:  Arun Pradhan; Andrew Dunn; Vladimir Ustiyan; Craig Bolte; Guolun Wang; Jeffrey A Whitsett; Yufang Zhang; Alexey Porollo; Yueh-Chiang Hu; Rui Xiao; Przemyslaw Szafranski; Donglu Shi; Pawel Stankiewicz; Tanya V Kalin; Vladimir V Kalinichenko
Journal:  Am J Respir Crit Care Med       Date:  2019-10-15       Impact factor: 21.405

Review 5.  Improved understanding of gastrointestinal stromal tumors biology as a step for developing new diagnostic and therapeutic schemes.

Authors:  Marta Magdalena Fudalej; Anna Maria Badowska-Kozakiewicz
Journal:  Oncol Lett       Date:  2021-03-28       Impact factor: 2.967

6.  Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Shinobu Tsuzuki; Takahiko Yasuda; Shinya Kojima; Masahito Kawazu; Koshi Akahane; Takeshi Inukai; Masue Imaizumi; Takanobu Morishita; Koichi Miyamura; Toshihide Ueno; Sivasundaram Karnan; Akinobu Ota; Toshinori Hyodo; Hiroyuki Konishi; Masashi Sanada; Hirokazu Nagai; Keizo Horibe; Akihiro Tomita; Kyogo Suzuki; Hideki Muramatsu; Yoshiyuki Takahashi; Yasushi Miyazaki; Itaru Matsumura; Hitoshi Kiyoi; Yoshitaka Hosokawa; Hiroyuki Mano; Fumihiko Hayakawa
Journal:  Blood Cancer Discov       Date:  2020-06-10

7.  E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.

Authors:  Joaquín Arribas; César Serrano; Alfonso García-Valverde; Jordi Rosell; Sergi Sayols; David Gómez-Peregrina; Daniel F Pilco-Janeta; Iván Olivares-Rivas; Enrique de Álava; Joan Maurel; Jordi Rubió-Casadevall; Anna Esteve; Marta Gut; Claudia Valverde; Jordi Barretina; Joan Carles; George D Demetri; Jonathan A Fletcher
Journal:  Oncogene       Date:  2021-10-07       Impact factor: 9.867

Review 8.  Enhancer reprogramming in tumor progression: a new route towards cancer cell plasticity.

Authors:  Luca Fagnocchi; Vittoria Poli; Alessio Zippo
Journal:  Cell Mol Life Sci       Date:  2018-04-24       Impact factor: 9.261

9.  Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.

Authors:  Ping Chi; Li-Xuan Qin; Bastien Nguyen; Ciara M Kelly; Sandra P D'Angelo; Mark A Dickson; Mrinal M Gounder; Mary L Keohan; Sujana Movva; Benjamin A Nacev; Evan Rosenbaum; Katherine A Thornton; Aimee M Crago; Sam Yoon; Gary Ulaner; Randy Yeh; Moriah Martindale; Haley T Phelan; Matthew D Biniakewitz; Sarah Warda; Cindy J Lee; Michael F Berger; Nikolaus D Schultz; Samuel Singer; Sinchun Hwang; Yu Chen; Cristina R Antonescu; William D Tap
Journal:  J Clin Oncol       Date:  2022-01-18       Impact factor: 44.544

Review 10.  Super-enhancer-mediated core regulatory circuitry in human cancer.

Authors:  Yuan Jiang; Yan-Yi Jiang; De-Chen Lin
Journal:  Comput Struct Biotechnol J       Date:  2021-05-05       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.